Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
Reducing Donor Specific HLA Antibody Strength in Maintenance Kidney Transplant Recipients (DSA Study)
An Exploratory, Open-Label, Single Center Study to Assess the Efficacy and Dose Titration of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Reducing Donor Specific HLA Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients
Status: Archived
Brody School of Medicine at East Carolina University
mi
from
Greenville, NC
Reducing Donor Specific HLA Antibody Strength in Maintenance Kidney Transplant Recipients (DSA Study)
An Exploratory, Open-Label, Single Center Study to Assess the Efficacy and Dose Titration of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Reducing Donor Specific HLA Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients
Status: Archived
Updated: 1/1/1970
Brody School of Medicine at East Carolina University
mi
from
Greenville, NC
Educating Missouri Patients About Preemptive Living Donor Transplantation
Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial
Status: Archived
Missouri Kidney Program
mi
from
Overland Park, KA
Educating Missouri Patients About Preemptive Living Donor Transplantation
Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial
Status: Archived
Updated: 1/1/1970
Missouri Kidney Program
mi
from
Overland Park, KA
Educating Missouri Patients About Preemptive Living Donor Transplantation
Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial
Status: Archived
Missouri Kidney Program
mi
from
Saint Louis, MO
Educating Missouri Patients About Preemptive Living Donor Transplantation
Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial
Status: Archived
Updated: 1/1/1970
Missouri Kidney Program
mi
from
Saint Louis, MO
Educating Missouri Patients About Preemptive Living Donor Transplantation
Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial
Status: Archived
Washington University
mi
from
St. Louis, MO
Educating Missouri Patients About Preemptive Living Donor Transplantation
Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Managing Chronic Kidney Disease in Eastern North Carolina
Management of Chronic Kidney Disease in Eastern North Carolina (MARKER)
Status: Archived
Brody School of Medicine at East Carolina University
mi
from
Greenville, NC
Managing Chronic Kidney Disease in Eastern North Carolina
Management of Chronic Kidney Disease in Eastern North Carolina (MARKER)
Status: Archived
Updated: 1/1/1970
Brody School of Medicine at East Carolina University
mi
from
Greenville, NC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Henderson, NV
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Henderson, NV
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
University of Arizona College of Medicine
mi
from
Tucson, AZ
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
University of Arizona College of Medicine
mi
from
Tucson, AZ
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
HealthwoRx South Florida Research Solutions
mi
from
Hollywood, FL
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
HealthwoRx South Florida Research Solutions
mi
from
Hollywood, FL
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Baptist Cardiac & Vascular Institute, Baptist Hospital of Miami
mi
from
Miami, FL
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Baptist Cardiac & Vascular Institute, Baptist Hospital of Miami
mi
from
Miami, FL
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Bingham Memorial Hospital
mi
from
Blackfoot, ID
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Bingham Memorial Hospital
mi
from
Blackfoot, ID
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Cardiology Associates of NW Indiana
mi
from
Munster, IN
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Cardiology Associates of NW Indiana
mi
from
Munster, IN
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Midwest Cardiovascular Research Foundation
mi
from
Davenport, IA
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Midwest Cardiovascular Research Foundation
mi
from
Davenport, IA
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Tristate Vascular Group
mi
from
Ashland, KY
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Tristate Vascular Group
mi
from
Ashland, KY
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Medical Center Bowling Green
mi
from
Bowling Green, KY
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Medical Center Bowling Green
mi
from
Bowling Green, KY
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
St. Joes's Hospital
mi
from
St. Paul, MN
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
St. Joes's Hospital
mi
from
St. Paul, MN
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
St Joseph Health Center
mi
from
St Charles, MO
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
St Joseph Health Center
mi
from
St Charles, MO
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Washington University
mi
from
St. Louis, MO
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Chambersburg Hospital
mi
from
Chambersburg, PA
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Chambersburg Hospital
mi
from
Chambersburg, PA
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Utah Cardiac Transplant Program
mi
from
Murray, UT
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
Utah Cardiac Transplant Program
mi
from
Murray, UT
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
VCU Medical Center
mi
from
Richmond, VA
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Post-Market Observation Study of Intra-Renal Drug Delivery (PROVIDE)
Status: Archived
Updated: 1/1/1970
VCU Medical Center
mi
from
Richmond, VA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Honolulu, HI
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Honolulu, HI
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Jeffersonville, IN
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jeffersonville, IN